Compare 8x8 Inc (EGHT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Organon & Co. Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $290.32M), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 12.4× 8x8 Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Organon & Co. Common Stock for 0 Days on average.
| EGHT | OGN | |
|---|---|---|
Market Cap | $290.32M | $3.61B |
Volume | 1,226,387 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $2.76 | $13.81 |
52-Week Low | $1.59 | $5.70 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $557.24M | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% today, with a mixed technical picture showing bullish oscillators but bearish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected profitability in 2026. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with substantial upside if the company achieves projected profitability, though current negative earnings and high debt levels pose execution risks. Institutional interest is growing with recent position increases, but the stock requires careful monitoring of Q3 2026 earnings results and debt management progress.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
